These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 36769359

  • 1. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
    Ogawa C, Tsuchiya K, Maeda K.
    Int J Mol Sci; 2023 Feb 03; 24(3):. PubMed ID: 36769359
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis.
    Li J, Xie QH, You L, Xu NX, Hao CM.
    Pharmacol Res; 2021 Jan 03; 163():105256. PubMed ID: 33086081
    [Abstract] [Full Text] [Related]

  • 5. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
    Rawee P, Eisenga MF.
    Ned Tijdschr Geneeskd; 2023 Sep 28; 167():. PubMed ID: 37823872
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A.
    Eur J Pharmacol; 2021 Dec 05; 912():174583. PubMed ID: 34678238
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice.
    Nakai T, Iwamura Y, Kato K, Hirano I, Matsumoto Y, Tomioka Y, Yamamoto M, Suzuki N.
    Blood Adv; 2023 Aug 08; 7(15):3793-3805. PubMed ID: 37146271
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S, PHI112844 Investigators.
    Am J Kidney Dis; 2016 Jun 08; 67(6):861-71. PubMed ID: 26827289
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Threshold of Serum Ferritin to Discriminate against Those at Greater Risk of Platelet Increase during Treatment with Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor.
    Ogawa C, Tsuchiya K, Tomosugi N, Maeda K.
    Acta Haematol; 2022 Jun 08; 145(4):412-418. PubMed ID: 35051929
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.